Intergroup RTOG 98-11: A phase III randomized study of 5-fluorouracil (5-FU), mitomycin, and radiotherapy versus 5-fluorouracil, cisplatin and radiotherapy in carcinoma of the anal canal

Reviewer: John P. Plastaras, MD, PhD
Abramson Cancer Center of the University of Pennsylvania
Last Modified: June 7, 2006

Presenter: J.A. Ajani
Presenter's Affiliation: M.D. Anderson Cancer Center, Houston, TX
Type of Session: Scientific


  • The current standard treatment of squamous cell carcinoma of the anus is concurrent chemoradiation (CRT) with 5-FU and mitomycin-C
  • The 5-yr disease free survival (DFS) is ~65%
  • Mitomycin-C has an undesirable side-effect profile, including prolonged thrombocytopenia, renal failure, and hemolytic uremic syndrome
  • The rationale for this study was to use cisplatin (CDDP)-based induction chemotherapy to shrink tumors prior to CRT in hopes of improving locoregional control

Materials and Methods

  • Phase III, multi-center randomized to:
  • Arm A: Standard 5-FU/mito-C concurrent CRT
  • 5-FU (1,000mg/m2 days 1-4 and 29-32) plus mitomycin (10mg/m2 days 1 and 29) and radiation (45 to 59 Gy)
  • Arm B: Induction chemotherapy 5-FU/CDDP
  • 5-FU (1,000mg/m2 days 1-4, 29-32, 57-60 and 85-88) plus cisplatin (75mg/m2 on days 1, 29, 57 and 85) and radiation (45 to 59 Gy; start day=57)
  • Patients:
    • Squamous cell carcinoma of the anus
    • 682 accrued, 598 analyzable
  • Stratification:
    • Gender, clinical nodal status, tumor diameter
  • Endpoints:
    • Primary: Disease-free survival.
    • Powered (80%) to detect a 10% DFS difference


  • Patient characteristics were balanced between the two arms:
    • median age was 55 yrs, 69% women
    • 28% had >5 cm tumor, 26% were clinical node positive
  • Disease free survival was not significantly different
    • 5-year estimated DFS was 56% for Arm A and 48% for Arm B (p=0.28)
  • Overall survival (5-year estimated) was 69% for both arms (p=0.24)
  • Colostomy rates were higher in the CDDP/5-FU induction arm:
    • 5-year colostomy rate was 10% for Arm A and 20% for arm B(p=0.12).
  • There was no significant difference in local control (33% vs. 26%)
  • Grade 3/4 toxicity rates favored CDDP/5-FU induction arm:
    • non-hematologic toxicity was 76% for Arm A and 75% for Arm B
    • hematologic toxicity was 67% for Arm A and 47% for Arm B (p=0.0004)

Author's Conclusions

  • Induction 5-FU/cisplatin followed by 5-FU/cisplatin/radiation failed to improve DFS compared to the standard treatment, 5-FU/mitomycin/radiation
  • The colostomy rate was higher in the 5-FU/cisplatin/radiation
  • The standard treatment arm should remain the standard

Clinical/Scientific Implications

  • The DFS not only was not improved by CDDP-based induction chemotherapy, but it actually trended toward the standard arm
  • The colostomy rate difference hints at a difference in local control/late RT effects that favored the standard arm, although there was no statistically significant difference in local control


Where Are the Adults in the Room?
by Rodney Warner, JD
November 20, 2015